ARQ 761

Drug Profile

ARQ 761

Alternative Names: ARQ 761

Latest Information Update: 08 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ArQule
  • Developer ArQule; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Hydroquinones; Small molecules
  • Mechanism of Action E2F1 transcription factor stimulants; NQO1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 02 Jun 2017 Safety and efficacy data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 09 Mar 2017 Arqule has patent protection for ARQ 761 in Canada (ArQule's form 10-K, filed in March 2017)
  • 04 May 2016 ArQule initiated enrolment in a phase Ib/II trial for Pancreatic cancer in USA before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top